Treatment of lymphangioleiomyomatosis: Building evidence in orphan diseases

European Respiratory Journal

Volumn 43, Issue 4, 2014, Pages 966-969

  Cottin, Vincent ^a,b  

^a LOUIS PRADEL HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; FULVESTRANT; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATRIX METALLOPROTEINASE 14; PLACEBO; RAPAMYCIN; SIMVASTATIN;

DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; HUMAN; LYMPHANGIOLEIOMYOMATOSIS; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; FEMALE;

DOXYCYCLINE; FEMALE; HUMANS; LYMPHANGIOLEIOMYOMATOSIS;

EID: 84897382017     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00025314     Document Type: Review

References (54)

1. Johnson SR, Cordier JF, Lazor R, et al European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35: 14-26.
2. Glasgow CG, El-Chemaly S, Moss J. Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 196-206.
3. Moss J, Avila NA, Barnes P.M., et al Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 2001; 164: 669-671.
4. Cudzilo CJ, Szczesniak RD, Brody A.S., et al Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest 2013; 144: 578-585.
5. Muzykewicz DA, Black ME, Muse V, et al Multifocal micronodular pneumocyte hyperplasia: computed tomographic appearance and follow-up in tuberous sclerosis complex. J Comput Assist Tomogr 2012; 36: 518-522.
6. Ryu JH, Sykes AM, Lee A.S., et al Cystic lung disease is not uncommon in men with tuberous sclerosis complex. Respir Med 2012; 106: 1586-1590.
7. Avila NA, Dwyer AJ, Rabel A, et al Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of ct features. Radiology 2007; 242: 277-285.
8. Cottin V, Harari S, Humbert M., et al Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J 2012; 40: 630-640.
9. Young LR, Vandyke R, Gulleman P.M., et al Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010; 138: 674-681.
10. Lazor R, Lauque D, Delaval P., et al Predictors of rapid decline of FEV1 in 50 cases of pulmonary lymphangioleiomyomatosis followed for ≥ year. Am J Respir Crit Care Med 2000; 161: A15.
11. Cottin V, Archer F, Leroux C., et al Milestones in lymphangioleiomyomatosis research. Eur Respir Rev 2011; 20: 3-6.
12. Carsillo T, Astrinidis A, Henske EP Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000; 97: 6085-6090.
13. Yu J, Astrinidis A, Henske EP Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med 2001; 164: 1537-1540.
14. Yu J, Henske EP mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis. Lymphat Res Biol 2010; 8: 43-49.
15. Bissler JJ, McCormack FX, Young L.R., et al Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151.
16. Bissler JJ, Kingswood JC, Radzikowska E, et al Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 817-824.
17. Franz DN, Leonard J, Tudor C., et al Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59: 490-498.
18. Franz DN, Belousova E, Sparagana S., et al Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (exist-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381: 125-132.
19. Krueger DA, Care MM, Holland K, et al Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363: 1801-1811.
20. McCormack FX, Inoue Y, Moss J., et al Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595-1606.
21. Moua T, Olson EJ, Jean H.C., et al Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy. Am J Respir Crit Care Med 2012; 186: 389-390.
22. Mohammadieh AM, Bowler SD, Silverstone E.J., et al Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis. Med J Aust 2013; 199: 121-123.
23. Taveira-DaSilva A.M., Hathaway O, Stylianou M., et al Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 2011; 154: 797-292.
24. Henske EP, McCormack FX Lymphangioleiomyomatosis - a wolf in sheep's clothing. J Clin Invest 2012; 122: 3807-3816.
25. Ando K, Kurihara M, Kataoka H., et al The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. Respir Investig 2013; 51: 175-183.
26. Hayashi T, Kumasaka T, Mitani K., et al Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinicopathologic study of 10 patients. Am J Surg Pathol 2011; 35: 1776-1785.
27. Crooks DM, Pacheco-Rodriguez G, DeCastro R.M., et al Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2004; 101: 17462-17467.
28. Kumasaka T, Seyama K, Mitani K., et al Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol 2005; 29: 1356-1366.
29. Mitani K, Kumasaka T, Takemura H., et al Cytologic, immunocytochemical and ultrastructural characterization of lymphangioleiomyomatosis cell clusters in chylous effusions of patients with lymphangioleiomyomatosis. Acta Cytol 2009; 53: 402-409.
30. El-Chemaly S., Henske EP Towards personalised therapy of lymphangioleiomyomatosis: lessons from cancer. Eur Respir Rev 2014; 23: 30-35.
31. McCormack FX, Travis WD, Colby T.V., et al Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 2012; 186: 1210-1212.
32. Odajima N, Betsuyaku T, Nasuhara Y., et al Matrix metalloproteinases in blood from patients with LAM. Respir Med 2009; 103: 124-129.
33. Chang WY, Cane JL, Blakey J.D., et al Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res 2012; 13: 34.
34. Hayashi T, Fleming MV, Stetler-Stevenson WG, et al Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol 1997; 28: 1071-1078.
35. Matsui K, Takeda K, Yu Z.X., et al Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000; 124: 267-275.
36. Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol 2013; 13: 649-665.
37. Chang WYC, Cane JL, Kumaran M, et al A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis. Eur Respir J 2014; 43: 1114-1123.
38. Castro MM, Kandasamy AD, Youssef N, et al Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res 2011; 64: 551-560.
39. Pimenta SP, Baldi BG, Kairalla R.A., et al Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response. J Bras Pneumol 2013; 39: 5-15.
40. Baldi BG, Carvalho CRR. Doxycycline in lymphangioleiomyomatosis: not all questions are answered. Eur Respir J 2014 [In press DOI: 10.1183/09031936. 00008114].
41. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for mmps. N Engl J Med 2006; 354: 2621-2622.
42. Taveira-DaSilva A.M., Hathaway OM, Moss J. Effect of progesterone (PG) and bisphosphonates (B) on bone mineral density (BMD) in patients with lymphangioleiomyomatosis (LAM). Am J Respir Crit Care Med 2004; 169: A225.
43. Johnson SR, Whale CI, Hubbard R.B., et al Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 2004; 59: 800-803.
44. Raghu G, Anstrom KJ, King TE Jr, et al Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.
45. Ingelfinger JR, Drazen JM Patient organizations and research on rare diseases. N Engl J Med 2011; 364: 1670-1671.
46. Spagnolo P, du Bois RM, Cottin V. Rare lung disease and orphan drug development. Lancet Respir Med 2013; 1: 479-487.
47. Kinder B, McCormack FX Clinical trials for rare lung diseases: lessons from lymphangioleiomyomatosis. Lymphat Res Biol 2010; 8: 71-79.
48. Li C, Zhou X, Sun Y., et al Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2013; 49: 135-142.
49. Shim B, Pacheco-Rodriguez G, Kato J., et al Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models. Eur Respir Rev 2013; 22: 302-311.
50. Yu J, Parkhitko A, Henske EP Autophagy: an "Achilles" heel of tumorigenesis in TSC and LAM. Autophagy 2011; 7: 1400-1401.
51. Goncharova EA, Goncharov DA, Li H, et al mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol 2011; 31: 2484-2498.
52. Atochina-Vasserman E.N., Goncharov DA, Volgina A.V., et al Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling. Am J Respir Cell Mol Biol 2013; 49: 704-709.
53. Seyama K, Kumasaka T, Souma S., et al Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006; 4: 143-152.
54. Nurok M, Eslick I, Carvalho C.R., et al The international LAM registry: a component of an innovative web-based clinician, researcher, and patient-driven rare disease research platform. Lymphat Res Biol 2010; 8: 81-87.